09/01/2025 - Press release
A multicenter study led by the Hospital del Mar Research Institute identifies five circulating microRNAs in the blood as potential markers for recovery in patients who have suffered a stroke. These small RNA molecules play a significant role in modulating the activity of genes linked to prognosis in ischemic stroke cases. The ability to regulate their activity could pave the way for new treatments to improve outcomes for individuals affected by this condition.
23/12/2024 - Institutional news
The Digestive Tumor Treatment Group (TTD) has awarded one of its grants for research projects on digestive tumors to Dr. Jenniffer Linares, a researcher from the Colorectal Cancer Precision Medicine Research Group, led by Dr. Clara Montagut at the Hospital del Mar Research Institute. The award ceremony took place during the 32nd TTD International Symposium on Advances in Digestive Tumor Treatments. The grant is for the project titled "Clinical impact of CAF-secreted biomarkers in RAS wild-type metastatic CRC patients treated within the CR-SEQUENCE clinical trial." Its goal is to identify the predictive value of biomarkers derived from the tumor microenvironment to anticipate the response to chemotherapy and anti-EGFR treatments in patients with RAS wild-type metastatic colorectal cancer.
Més informació "Grant from the Digestive Tumor Treatment Group for Dr. Jenniffer Linares"
18/12/2024 - Institutional news
At the congress commemorating the institution's tenth anniversary, held in Valencia from November 27 to 29. The PENSA project, driven by the Hospital del Mar Research Institute and the Barcelona βeta Brain Research Center, received one of the awards for the best communications at the congress of the Centro de Investigación Biomédica en Red (CIBERISCIII). This event marked the tenth anniversary of the scientific institution.
Més informació "CIBER Awards the PENSA Project of the Hospital del Mar Research Institute"
17/12/2024 - Press release
Phase 1/2 of the clinical trial shows that the administration of the AEF0217 molecule developed by the biotech Aelis Farma, is safe and can improve key skills such as communication, social interactions and daily living for people with Down syndrome These results reinforce the start of the phase 2 clinical trial, through an international multicenter study with people with Down syndrome, focused on the dose necessary to achieve the treatment goal
16/12/2024 - Institutional news
The work of the Catalonia Anti-Doping Laboratory in the field of innovation and research has been recognized by the Catalan Sports Foundation at the eighth edition of the Sports Awards. The award highlighted the laboratory's research and innovation activities for clean sport, which have earned international recognition. A delegation led by Rosa Ventura, the laboratory's director, and five team members-Sergi Coll, Imma Figuera, Lídia Requena, Susana Cuadras, and Claudia Bressan-attended the award ceremony.
12/12/2024 - General information
The SAGITTARIUS clinical trial has officially begun with the inclusion of the first six patients in the project. Among them, the first at the Hospital del Mar, a collaborating center in the study, which is coordinated in Spain by Dr. Clara Montagut, head of the Gastrointestinal Tumors section of the Medical Oncology Service and coordinator of the Colorectal Cancer Precision Medicine Research Group at the Hospital del Mar Research Institute.
Més informació "The SAGITTARIUS clinical trial, led by the Hospital del Mar in Spain, gets underway"
11/12/2024 - Press release
Consuming 20-30% of daily energy intake in the morning influences key cardiovascular risk factors. People who consume the right amount of energy in the morning have 2-3.5% lower body mass index, less abdominal obesity (2-4% smaller waist circumference), 9-18% lower triglycerides, and 4-8.5% higher HDL cholesterol (the good cholesterol). Additionally, having a high-quality breakfast with a balanced intake of proteins, high-value fats, fiber, calcium, and iron is associated with a 1.5% smaller waist circumference, 4% lower triglycerides, and 3% higher HDL cholesterol. The study tracked nearly 400 participants of the PREDIMED-Plus study over three years, which analyzes the effects of the Mediterranean diet on participants' health.
Més informació "Having a good breakfast reduces cardiovascular risk"
04/12/2024 - General information
She will hold the position for two years and will be responsible for reviewing and supervising the evaluation processes of each call within her field at the agency. Dr. Esther Barreiro, an associate physician in the Pulmonology Service at Hospital del Mar and a researcher at its research institute, has been appointed as the coordinator in the field of medical and health sciences at the Agency for the Management of University and Research Grants (AGAUR).
02/12/2024 - Press release
A study by the Hospital del Mar Research Institute, in collaboration with the University of Vic-Central University of Catalonia (UVic-UCC), published in the Revista Española de Cardiología, validates the effectiveness of this type of initiative. Implementing out-of-hospital care programs reduces the fatality rate of heart attacks by 35% and long-term mortality by 27%.
26/11/2024 - General information
They are included in the list of the 6,636 most cited researchers worldwide, compiled once again this year by the company. Two researchers from the Hospital del Mar Research Institute are once again among the most cited in the world, according to the Highly Cited Researcher ranking recently published by Clarivate Plc, a company specializing in bibliometrics, business intelligence, and market analysis. The researchers are Dr. Jordi Alonso and Dr. Joaquim Bellmunt, who have been recognized for the relevance of their published studies within their respective fields of expertise.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
